Peptide Atlas · Peptide

TB-500

Analysis of the product sold as TB-500 identified the N-terminally acetylated 17-23 fragment of human thymosin beta 4, Ac-LKKTETQ.

preclinical

provisional
PubChem 62707662
2 citations
0 discussions
0 followers

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

preclinical — animal, cell or mechanistic work — not yet about people

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

- preclinical
  Claim: Review: active sites of thymosin beta 4 in short peptide sequences standing
- resolved
Biological activities of thymosin beta4 defined by active sites in short peptide sequences.
Sosne G, Qiu P, Goldstein AL, Wheater M
pmid 20179146
- unknown
  Claim: Identification of Ac-LKKTETQ in TB-500 by high-resolution mass spectrometry standing
- resolved
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.
Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P
pmid 22962027

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.